I led the Lilly Value and Access (LVA) Value Excellence team for two years. The Value Excellence team:- Created value-based price recommendations for Lilly USA product launches and lifecycle pricing; team developed launch price recommendations for Kisunla, Zepbound, Zepbound vial, and Ebglyss. - Led Value-Based Agreement (VBA) strategy development and execution support for brands across all therapeutic areas- Implemented a value frameworks strategy, with focus on ICERI am actively involved in recruiting, mentorship, and diversity/equity/inclusion (DEI) initiatives across Lilly.

Part of business development teams who analyze opportunities to partner, in-license, acquire, and divest assets across all therapeutic areas at Lilly. - Valued business development opportunities across all therapeutic areas, including in-licensing, divestment, partnership, and acquisition structures- Lead of Finance Functional Diversity & Inclusion Committee and Finance, Procurement, and GBS Women's Network. Setting team goals, managing communications, and creating events to build organizational capabilities around diversity and inclusion. Team's work resulted in function-wide increase in pulse scores related to inclusion. FPWN events routinely reach 130+ attendees with near 100% event satisfaction.Disclosed transactions: • License of oral P2X7 receptor antagonist from Asahi Kasei for chronic pain• License of WellDoc insulin management software for diabetes management• Acquisition of Protomer Technologies, a peptide and protein engineering platform for glucose-sensing insulin• License, strategic collaboration, and equity investment in Regor Therapeutics for metabolic disorders• Research and collaboration agreement with Entos Pharmaceuticals, for proteo-lipid vehicles (PLVs) and central nervous system (CNS) delivery

I supported the US Connected Care and Glucagons marketing and sales teams within our Diabetes Business Unit, including: - Managed financial planning, forecasting, and reporting activities for US Glucagon brand P&L ($90M+ in annual revenue)- Increased forecasting accuracy for both brands in a volatile COVID-influenced commercial environment- Partnered with cross-functional brand management team and identified opportunities for savings- Consolidated $8B Diabetes Business Unit financial scorecard in short term assignment

I performed budgeting, planning (FP&A), and financial strategy for Lilly Oncology.- Led analysis for 2019 R&D financial strategic plan, consolidating $5B+ in annual R&D forecasts, preparing review materials, and presenting to senior leadership- Coordinated forecasting, planning, and reporting (FP&A) for oncology R&D expenses including short-term forecasting, long-term forecasting, and monthly controls- Developed business cases for internal investment opportunities in oncology assets

Self-Help is a community development lender that has provided over $6 billion in financing to help more than 75,000 borrowers buy homes and build businesses across the country. It was featured in the book "Forces for Good: The Six Practices of High-Impact Nonprofits."​ Its SBA 504 Loan program helps small businesses finance owner-occupied real estate and equipment purchases.

Supported 3,500+ Chamber members through workshops, conferences and government engagement at the largest Chamber of Commerce in the Asia-Pacific.

Developed the Chamber's 2010 World Expo Business Series including three conferences (Auto Conference, Sustainability Conference and Innovation Forum), CEO Speaker Series, and Urban Planning Series. Our outreach for the CEO speaker series led to 6 global-level CEO speeches to our membership.